Fannie Mae, Freddie Mac shares tumble after conservatorship comments
GREENWICH, Conn. - Deep Track Capital, LP, a significant shareholder of Dynavax Technologies Corporation (NASDAQ: DVAX), has publicly advocated for substantial changes to the company’s Board of Directors. The investment firm, which holds approximately 14.82% of Dynavax’s shares in the $1.23 billion market cap company, has proposed four nominees for election at Dynavax’s Annual Meeting on June 11, 2025, to address what it perceives as strategic missteps and market share stagnation of the company’s key vaccine product, Heplisav. According to InvestingPro data, DVAX shares have declined over 20% in the past six months, underperforming the broader market.
Deep Track’s nominees, Brett Erkman, Jeffrey Farrow, Michael Mullette, and Donald Santel, are positioned as independent voices aimed at refocusing the company’s strategic direction and improving capital allocation. The firm’s letter to shareholders highlights a series of concerns, including Dynavax’s failure to meet its own sales and market share targets for Heplisav. According to the company’s 2024 results, Heplisav U.S. sales were $7 million below the $275 million target, and its U.S. market share in the fourth quarter was 3 percentage points short of the 47% goal. InvestingPro data shows the company maintains strong liquidity with a current ratio of 11.93 and holds more cash than debt on its balance sheet, suggesting financial flexibility despite operational challenges.
The investment firm argues that Dynavax’s share price has suffered due to a lack of coherent strategy for its cash reserves and an overemphasis on diversifying away from Heplisav. Deep Track contrasts Dynavax’s stock performance unfavorably with the Nasdaq Biotechnology Index, noting a more significant decline over one-, two-, and three-year periods. Based on InvestingPro Fair Value analysis, the stock appears fairly valued, though analysts maintain an average price target significantly above current levels. The company has shown revenue growth of nearly 25% in the last twelve months, despite current challenges.
Deep Track’s campaign has received support from Glass, Lewis & Co., a leading proxy advisory firm, which has echoed concerns about Dynavax’s strategic direction and board responsiveness. The proxy advisory firm has recommended electing Deep Track’s directors to bring fresh perspectives to the board.
The current board has been accused by Deep Track of baseless mischaracterizations of the investment firm and its nominees. Deep Track insists that its nominees are committed to acting in the best interest of all shareholders and refutes the idea that it is seeking short-term gains.
This push for board changes comes at a critical time for Dynavax, as the company’s classified board structure means that the 2025 Annual Meeting presents a rare opportunity for shareholders to influence the board’s composition significantly. The information in this article is based on a press release statement from Deep Track Capital. For comprehensive analysis of DVAX and access to additional financial metrics, including 8 key ProTips and detailed valuation models, visit InvestingPro, where you’ll find the complete Pro Research Report covering what really matters for informed investment decisions.
In other recent news, Dynavax Technologies Corporation reported a 36% increase in first-quarter net sales for its HEPLISAV-B vaccine, boosting its market share to 43%. The company anticipates its year-end net sales to align with the upper half of its $305 million to $325 million guidance range for 2025. Additionally, Dynavax is advancing its research and development with plans to trial an H5N1 influenza vaccine this year and a Lyme disease vaccine by 2027. Meanwhile, Citizens JMP adjusted its price target for Dynavax from $33.00 to $31.00, maintaining a Market Outperform rating due to the company’s promising start to the second quarter of 2025. In corporate governance news, the upcoming Annual Meeting on June 11 will see a contested proxy vote, with Deep Track Capital advocating for its nominees to join the Dynavax board. Glass Lewis, a proxy advisory firm, has recommended support for two of Deep Track’s nominees, citing concerns about Dynavax’s strategic direction and capital allocation. Dynavax counters by emphasizing its long-term strategy, highlighting a 203% return to stockholders over five years. The company is urging shareholders to support its current board to maintain its strategic momentum.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.